At this year’s annual congress of the American Academy of Dermatology (AAD), Incyte (Nasdaq: INCY) has announced new one-year results for Opzelura (ruxolitinib cream).
The product is being studied in vitiligo, a chronic autoimmune disease characterized by depigmentation of the skin.
The Delaware, USA-based firm is testing the topical JAK1/JAK2 inhibitor, which is formulated as a cream, in the Phase III TRuE-V trial.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze